Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
FLNA Stock — Filana Therapeutics, Inc.
Filana Therapeutics, Inc. (FLNA)
Updated October 16, 2026.
FLNA is a Stock. Total return is -99.2% over the past 26.3 years, 802.6 points behind SPY at 703.4%.
Filana Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, with its lead candidate simufilam in Phase 3 trials for Alzheimer's disease and an early-stage blood-based diagnostic program called SavaDx. The company does not currently distribute dividends. Filana appeals primarily to investors seeking exposure to clinical-stage biotech development rather than current income.
FLNA dividend yield and income
Price as of 2026-10-16.
The ex-dividend date is 12/13/2012. The payment date is 12/24/2012.
| Ex-date | As paid | Per current share | Change from previous payment |
|---|---|---|---|
| 2012-12-13 | $0.75 | $5.25 | -62.5% Unclassified cash |
| 2010-12-13 | $2 | $14 | — |
| 2010 total | — | $14 | — |
| 2012 total | — | $5.25 | -62.5% |
FLNA performance versus SPY
Price and return data through 2026-10-16.
Total return is -99.2% over the past 26.3 years, 802.6 points behind SPY at 703.4%. Over the past year its total return — price change plus distributions reinvested — is -84.4%. Its deepest 1-year drawdown was 85.0%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | 3.5% | — |
| 3M | -34.9% | — |
| 6M | -60.0% | — |
| YTD | -64.5% | — |
| 1Y | -84.4% | — |
| 2Y CAGR | — | -84.60% |
| 3Y CAGR | — | -61.80% |
| 5Y CAGR | — | -57.30% |
| 10Y CAGR | — | -18.00% |
| Since inception (26.3 years) | -99.2% | -16.80% |
FLNA key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 07/14/2000
- Distribution frequency
- None
- Last close
- $0.70 (as of 2026-10-16)
- Market cap
- $33,984,605
- Average volume
- 327927.0
- Ex-dividend date
- 12/13/2012
- Payment date
- 12/24/2012
- Beta
- -0.66
- Payout ratio
- 0.0%
- Forward P/E
- 151.5152
- EPS
- $-0.87
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
FLNA risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 85.0%.
Who may consider FLNA — and who may not
It is a weaker fit for investors who need monthly cash flow (FLNA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on FLNA
Frequently asked questions
Does FLNA pay monthly?
No. FLNA does not currently distribute.
When does FLNA pay a dividend?
FLNA does not currently distribute. The ex-dividend date is 12/13/2012. The payment date is 12/24/2012.
How has FLNA performed?
Total return is -99.2% over the past 26.3 years, 802.6 points behind SPY at 703.4%. Over the past year its total return — price change plus distributions reinvested — is -84.4%. Its deepest 1-year drawdown was 85.0%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.